View source for 20250163150. Combination Therapi (I-Mab Biopharma US Limited)

= COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER =

'''Abstract''':
provided herein are methods of treating a kras mutant cancer (e.g., a kras g12c mutant cancer or a kras g12d mutant cancer) in a subject, comprising administering to the subject an effective amount of an agent that blocks the interaction between cd47 and sirp� and an effective amount of a kras inhibitor (e.g., a kras g12c inhibitor wherein the cancer is a kras g12c mutant cancer, or a kras g12d inhibitor wherein the cancer is a kras g12d mutant cancer). also provided are methods of stimulating phagocytosis of a population of cancer cells that express a kras mutant protein (e.g., a kras g12c mutant protein or a kras g12d mutant protein) by macrophages, comprising contacting the population with an effective amount of a therapeutic agent that blocks the interaction between cd47 and sirp� and an effective amount of a kras inhibitor (e.g., a kras g12c inhibitor wherein the kras mutant protein is a kras g12c mutant protein, or a kras g12d inhibitor wherein the kras mutant protein is a kras g12d mutant protein).

'''Inventor(s)''': [[:Category:Yanni ZHANG of Shanghai  CN|Yanni ZHANG]], [[:Category:Ke XU of Shanghai  CN|Ke XU]], [[:Category:Zhengyi WANG of Shanghai  CN|Zhengyi WANG]]

'''CPC Classification''': [[:Category:CPC_C07K16/2803|C07K16/2803]] (PEPTIDES  (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))


[[Category:Patent Applications]]
[[Category:I-Mab Biopharma US Limited]]
[[Category:CPC_C07K16/2803]]
[[Category:Yanni ZHANG of Shanghai  CN]]
[[Category:Ke XU of Shanghai  CN]]
[[Category:Zhengyi WANG of Shanghai  CN]]

[https://wikipatents.org/index.php?search=20250163150+rejection&title=Special%3ASearch&wprov=acrw1_-1 Search for rejections for patent application number 20250163150]


<!-- JSON-LD markup for search engines:
{"@context":"https://schema.org","@type":"TechArticle","headline":"20250163150. Combination Therapi (I-Mab Biopharma US Limited)","name":"20250163150. Combination Therapi (I-Mab Biopharma US Limited)","description":"Patent application abstract and classification for 20250163150 - Combination Therapi","datePublished":"2025-05-25","mainEntity":{"@type":"GovernmentPermit","permitType":"Patent Application","identifier":"20250163150","name":"Combination Therapi","additionalProperty":[{"@type":"PropertyValue","name":"Organization","value":"I-Mab Biopharma US Limited"}]}}
-->